Can Moderna Repeat COVID-19 Success In Influenza Market?

First Subject Dosed In Flu Vaccine Trial

 
• By Alaric DeArment

The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.  

Influenza A H7N9
Moderna announced that the first subject in its Phase I/II study of its mRNA influenza vaccine was dosed • Source: Shutterstock

More from Anti-infective

More from Therapy Areas